Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
22 Aspirin Trials
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Postpartum Aspirin for Blood Clots
Toronto, OntarioThe goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Female
8805 Participants Needed
Clopidogrel vs. Aspirin for Staph Bloodstream Infection
Montreal, QuebecThis is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.
Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).
If positive, this study will support a second RCT in people who do not currently have an indication for clopidogrel.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
300 Participants Needed
Aspirin + Warfarin for Congestive Heart Failure
New York, New YorkHeart failure is a world epidemic. LVADs are increasingly used as they have demonstrated improved survival rates compared to optimal medical management. Improving outcomes have been seen with the newer LVAD technology, the HeartMate 3 (Abbott, Chicago, IL), however, hemocompatibility related adverse events, including thrombosis and bleeding, are still a major cause of morbidity and mortality. The recent ARIES trial showed that in patients with advanced heart failure treated with a HeartMate3 LVAD, avoidance of aspirin as part of an antithrombotic regimen, which includes vitamin K antagonist (VKA), is not inferior to a regimen containing aspirin, does not increase thromboembolism risk, and is associated with a reduction in bleeding events.
This clinical investigation is a prospective, randomized, controlled study of advanced heart failure patients supports with the HeartMate3 for more then 3 months with two different antithrombotic regimens: VKA with and without aspirin. The objective of this investigation is to study the safety and efficacy of an antithrombotic regimen without antiplatelet therapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Other Clinical Trials, Others
Must Be Taking:Aspirin, VKA
128 Participants Needed
Antiplatelet Therapy for Vascular Disease
New Orleans, LouisianaPatients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:45+
Sex:All
100 Participants Needed
Omeprazole + Aspirin for Colorectal Cancer
Columbus, OhioThis trial will obtain biomarker data on the possible preventive effects of omeprazole and low-dose aspirin in colorectal tissue. Persons who have had 5 or more adenomas, 5 or more serrated polyps, or an incompletely removed adenoma or serrated polyp in the colon or rectum are potentially eligible. Before participating in the study, study staff will explain the study and review the consent form. If you are interested and provide consent, study staff will then confirm your eligibility. Once enrolled, participants will take two 20 mg omeprazole tablets and two 81 mg aspirin tablets each day before the first meal each day for 25-45 days.
The study does involve biopsies of the colorectal tissue before and after taking the study medications. The biopsies are samples of tissue, about the size of a grain of rice, that will be taken from the colon or rectum before and after taking the study medications. This is done during a usual, clinical colonoscopy exam and during one more limited exam, called flexible sigmoidoscopy, that is done for the research study. The flexible sigmoidoscopy requires less preparation. Which procedure comes first depends on what fits best with each participant's clinical scenario. Biopsies of both normal mucosa and polyps (if possible) are collected.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Age 76+, Genetic Syndromes, Cancer, Others
Must Be Taking:Omeprazole, Aspirin
24 Participants Needed
Aspirin for Endometriosis
University Park, PennsylvaniaThe goal of this clinical trial is to compare neurovascular regulation in women with endometriosis and healthy women. The main questions it aims to answer are:
* Do women with endometriosis have greater blood pressure and pain responses to a stimulus than healthy women?
* Do women with endometriosis have greater platelet activity than healthy women?
Participants will take aspirin and/or placebo and will:
* perform hand grip exercise and cold pressor tests
* undergo iontophoresis and blood draw
Researchers will compare women with and without endometriosis to see if there is a difference in neurovascular regulation.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Diabetes, Hypertension, Others
Must Be Taking:Aspirin
96 Participants Needed
Aspirin for Preeclampsia
Iowa City, IowaWomen who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 50
Sex:Female
Key Eligibility Criteria
Disqualifiers:Tobacco Use, Hepatic Disease, Hypertension, Others
Must Not Be Taking:Aspirin, Statins, Antihypertensives
40 Participants Needed
Aspirin for Preeclampsia Prevention
New York, New YorkThis trial is testing low-dose aspirin to prevent preeclampsia in pregnant women, especially Black women who may have higher rates of aspirin failure. Aspirin works by preventing blood clots and improving blood flow in the placenta. Low-dose aspirin has been studied for a long time for its potential to prevent preeclampsia, with mixed results.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Chronic Hypertension, Diabetes, Others
Must Be Taking:Low-dose Aspirin
130 Participants Needed
Aspirin for Colorectal Cancer
Boston, MassachusettsThis research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer.
The name of the study intervention involved in this study is:
* Low Dose Aspirin
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
161 Participants Needed
Platelet Activity Assay for Blood-Thinner Monitoring in Obese Individuals
Boston, MassachusettsThe purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy volunteers and severely obese individuals and comparing the accuracy of the two tests. The secondary goals will be to evaluate the pharmacodynamic parameters of the antiplatelet agents across the two testing modalities and refine the cutoffs used for the novel assay.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cirrhosis, Cancer, Others
Must Not Be Taking:Antiplatelets, Anticoagulants, Antidepressants, Others
125 Participants Needed
Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Bleeding Disorder, Low Platelet Count, Others
Must Not Be Taking:Anticoagulants
135 Participants Needed
Niacin and Aspirin for Prostaglandin D2 Metabolism Pathways
Nashville, TennesseeThis trial uses niacin and aspirin to study their effects on a body chemical in healthy volunteers. Researchers measure chemicals in urine and blood to understand how this chemical is broken down.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Early Phase 1
Age:18 - 65
Sex:All
10 Participants Needed
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active Endocarditis, Hepatitis, Anemia, Others
Must Not Be Taking:Anticoagulants, Antiplatelets
700 Participants Needed
Moxetumomab + Rituximab/Ruxience for Hairy Cell Leukemia
Bethesda, MarylandBackground:
Hairy cell leukemia (HCL) is a rare, slow-growing blood cancer in which the bone marrow makes too many of certain white blood cells. The antibody Rituximab/Ruxience binds to a protein in cancerous white blood cells and is often used to treat HCL. Researchers want to see if combining it with the drug Moxetumomab pasudotox-tdfk (also called Lumoxiti) can fight HCL better.
Objective:
To test the safety of Moxetumomab pasudotox taken with Rituximab/Ruxience for people with HCL or HCL variant.
Eligibility:
People age 18 years and older with HCL or HCL variant that has not responded to standard therapy
Design:
Participants will be screened with:
Medical history
Physical exam
Blood, heart, and urine tests
Test of blood oxygen levels
Review of bone marrow. This can be from previous test results or a new sample.
Scans
Exercise test
Participants will get the study drugs in up to 8 cycles. A cycle will last about 28 days.
The study drugs will be given through a plastic tube in a vein.
In the first week of cycle 1, participants will have:
1 visit to get Rituximab or Ruxience for 7.5 hours
3 visits to get Lumoxiti for 30 minutes per infusion
In the first week of cycles 2-8, participants will have:
1. visit to get Rituximab/Ruxience for 2-4 hours and Lumoxiti for 30 minutes
2. visits to get Lumoxiti for 30 minutes per infusion
Participants will be asked to drink lots of water and take aspirin during the cycles. They will get drugs to minimize allergic reactions.
Participants will repeat screening tests at visits throughout the cycles and 1 follow-up visit. They may have an eye exam.
...
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
18 Participants Needed
Aspirin for Ankle Fracture Healing
Birmingham, AlabamaThis study aims to identify if postoperative aspirin use leads to a delay in fracture healing. NSAIDs have long been avoided in the management of fractures, due to the belief that they may impair fracture healing. As aspirin is frequently prescribed for long-term management of various medical conditions, it is worth understanding if continuing to take aspirin during the process of fracture healing has a clinically significant effect on the rate of fracture healing.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
500 Participants Needed
Aspirin for Acoustic Neuroma
Iowa City, IowaThis trial is testing whether aspirin can slow tumor growth and improve hearing in patients aged 12+ with vestibular schwannomas. Aspirin's anti-inflammatory properties might help achieve these effects. Aspirin has been studied for its potential to protect against certain types of hearing loss and has shown some protective effects in previous studies.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Asthma, Hydrocephalus, Others
Must Not Be Taking:Aspirin
300 Participants Needed
Aspirin for Sleep Deprivation-Related Inflammation
Boston, MassachusettsThis trial is testing if a small amount of aspirin can reduce inflammation caused by irregular sleep patterns in healthy adults. The study focuses on people who restrict sleep for several days and then catch up later. Aspirin helps the body produce substances that turn off inflammation, which might be disrupted by these sleep patterns.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:18 - 65
Sex:All
66 Participants Needed
Intensive Cardiovascular Medication for Coronary Artery Disease
Springfield, OhioThe Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) trial is a multicenter, prospective, randomized, blinded outcome evaluation (PROBE design) evaluating intensive statin/ACE-I (or ARB)/aspirin treatment (IMT) vs. usual care (UC) in 4,422 symptomatic women patients with symptoms and/or signs of ischemia but no obstructive CAD. The hypothesis is that IMT will reduce major adverse coronary events (MACE) 20% vs. UC. The primary outcome is first occurrence of MACE as death, nonfatal MI, nonfatal stroke/transient ischemic attack (TIA) or hospitalization for heart failure or angina. Secondary outcomes include quality of life, time to "return to duty"/work, health resource consumption, angina, cardiovascular (CV) death and primary outcome components. Events will be adjudicated by an experienced Clinical Events Committee (CEC). Follow-up will be 3-years using 50 sites: primarily VA and Active Duty Military Hospitals/Clinics and a National Patient-Centered Clinical Research Network (PCORnet) clinical data research network (CDRN)(OneFlorida Consortium).
This study is being conducted to determine whether intensive medication treatment to modify risk factors and vascular function in women patients with coronary arteries showing no flow limit obstruction but with cardiac symptoms (i.e., chest pain, shortness of breath) will reduce the patient's likelihood of dying, having a heart attack, stroke/TIA or being hospitalized for cardiac reasons. The results will provide evidence data necessary to inform future guidelines regarding how best to treat this growing population of patients, and ultimately improve the patient's cardiac health and quality of life and reduce health-care costs.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:18 - 100
Sex:Female
2476 Participants Needed
Aspirin for Preventing Colorectal Cancer in Patients With Adenomas
Nashville, TennesseeThis phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
81 Participants Needed
Multiple Treatments for Pneumonia
Columbus, OhioREMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Healthcare-associated Pneumonia, Imminent Death, Others
20000 Participants Needed
Aspirin for Barrett's Esophagus
Chicago, IllinoisThis randomized phase II trial studies the safety of and how well aspirin works in preventing Barrett's esophagus from returning after it has been successfully eliminated by radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus for the levels of a specific protein that is linked to developing Barrett's esophagus may help doctors learn whether aspirin can prevent it from returning after it has been successfully treated.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
21 Participants Needed
Aspirin for Colorectal Cancer Prevention
Boston, MassachusettsThis research study is investigating the use of aspirin as a potential chemopreventive agent to reduce risk of colorectal cancer
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
180 Participants Needed
Page 1 of 1+
Frequently Asked Questions
How much do clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest clinical trials ?
Most recently, we added Postpartum Aspirin for Blood Clots, Clopidogrel vs. Aspirin for Staph Bloodstream Infection and Aspirin + Warfarin for Congestive Heart Failure to the Power online platform.